




RealRate

PHARMACEUTICAL 2020

Theravance Biopharma Inc
Rank 148 of 363

Theravance
Biopharma 
Medicines That Make a Difference®



The relative strengths and weaknesses of Theravance Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theravance Biopharma Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Theravance Biopharma Inc is the variable Research and Development, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 274%, being 36% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	338,488
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	111,703
Liabilities, Non-Current	0
Other Assets	57,694
Other Compr. Net Income	311
Other Expenses	26,640
Other Liabilities	0
Other Net Income	42,100
Other Revenues	73,414
Property and Equipment	12,644
Research and Development	219,248
Selling, General and Administrative Expense	106,081

Output Variable	Value in 1000 USD
Assets	408,826
Liabilities	111,703
Expenses	351,969
Revenues	73,414
Stockholders Equity	297,123
Net Income	-236,455
Comprehensive Net Income	-236,300
BaseVar	494,162
ECR before LimitedLiability	158%
Economic Capital Ratio	274%